Lancet Study Links 1.9 Lakh Indian Cancers to Infections
Wednesday, 30 September 2026 – A new analysis in Lancet Oncology estimates that almost 1.9 lakh (190,000) cancer cases in India this year can be traced back to viral or bacterial infections, officials said. The figure represents roughly 12% of all new cancer diagnoses nationwide, according to the study that pooled data from more than 30 Indian cancer registries spanning the last decade.
- 190,000 cases linked to infections
- 12% share of total cancer burden
- Data drawn from 30 registries
The researchers highlighted human papillomavirus (HPV), hepatitis B virus (HBV), hepatitis C virus (HCV) and Helicobacter pylori as the leading infectious agents.
The study's lead author, Dr. Sharmila Ghosh of the All India Institute of Medical Sciences, said the findings underscore a preventable slice of the nation's cancer epidemic.
This is the first time a single peer‑reviewed paper has quantified infection‑related cancers for the whole country, making the numbers a benchmark for public‑health planning.
The Lancet team used age‑standardised incidence rates and adjusted for regional variations, allowing a granular view that shows some states, such as West Bengal and Gujarat, have higher infection‑linked rates than the national average.
The analysis also accounted for latency periods—particularly for HBV‑related liver cancer, which can emerge decades after initial infection—thereby providing a more realistic estimate of the future burden as India's population ages.
Importantly, the authors stress that the 12% figure is not static; it could rise if vaccination coverage stalls or if antimicrobial resistance hampers H. pylori eradication programmes.
Historical Trends: From 1990s to 2026, A Growing Preventable Burden
India's cancer landscape has shifted dramatically over the past three decades. In the early 1990s, tobacco‑related lung cancers dominated, accounting for nearly 20% of all cases. By the 2010s, lifestyle diseases and urban pollution rose, but infection‑related cancers remained under‑reported due to limited surveillance. The National Cancer Registry Programme, launched in 1982, only began systematic infection tracking in 2005, when the Indian Council of Medical Research (ICMR) funded pilot studies on HPV prevalence. Those early efforts laid the groundwork for the 2026 Lancet analysis, which benefits from a decade of richer data. Over the last 15 years, cervical cancer incidence has fallen by 15% in states with school‑based HPV vaccination, yet the absolute number of cases remains high because of a large population base. Meanwhile, hepatitis B vaccination, introduced into the universal immunisation programme in 2002, has cut new HBV infections by 40% nationally, according to Ministry of Health figures. Despite these gains, the Lancet study warns that without accelerated roll‑out, infection‑linked cancers could rise as life expectancy climbs and more people survive other diseases, exposing them to long‑term infection risks. The trend mirrors global patterns: the World Health Organization estimates that 1 in 8 cancers worldwide is infection‑related, a proportion that India now mirrors at roughly 12%. Regional disparities are stark; West Bengal's higher HPV prevalence aligns with its elevated cervical cancer rates, while Gujarat's industrial water‑use patterns correlate with increased H. pylori infection and gastric cancer. These patterns suggest that socioeconomic and environmental factors intersect with infectious risk, shaping a complex epidemiological mosaic.
Policy Implications and Prevention Strategies
The Lancet findings arrive at a policy crossroads. First, they reinforce the urgency of scaling up the national HPV vaccination programme, which currently reaches about 55% of eligible girls. Modeling studies suggest that achieving 90% coverage could avert up to 70,000 cervical cancer cases over the next two decades, directly shaving off a sizable portion of the infection‑related burden. Second, the data bolster calls for universal hepatitis B birth‑dose administration; while the vaccine is part of the routine schedule, gaps in cold‑chain logistics leave rural districts with sub‑optimal coverage. Strengthening supply chains and integrating point‑of‑care testing could close this gap. Third, H. pylori eradication—once considered a low‑priority public‑health issue—now warrants systematic screening in high‑prevalence districts such as Gujarat and Punjab. Pilot programmes using non‑invasive stool antigen tests have demonstrated 80% cure rates when paired with clarithromycin‑sparing regimens, a crucial consideration given rising antibiotic resistance. Finally, the study underscores the need for a coordinated surveillance framework that links cancer registries with infectious‑disease reporting systems. Such integration would enable real‑time monitoring of infection‑related cancer trends and allow rapid policy adjustments. The Ministry of Health has announced a task force to draft an "Infection‑Related Cancer Action Plan" by early 2027, aiming to align vaccination, screening, and treatment pathways under a single umbrella.
Future Research Directions and Global Context
While the Lancet analysis provides the most comprehensive snapshot to date, several knowledge gaps remain. Longitudinal cohort studies are needed to clarify the latency between initial infection and malignant transformation, especially for HBV and HCV where co‑factors such as alcohol use and aflatoxin exposure amplify risk. Molecular epidemiology could also identify viral sub‑types that are more oncogenic, guiding targeted vaccine updates. On the global stage, India's experience offers a template for other low‑ and middle‑income countries grappling with similar dual burdens of infectious disease and rising non‑communicable diseases. Comparative analyses with Brazil and sub‑Saharan Africa—regions where HPV and hepatitis also drive cancer incidence—could reveal best practices for vaccine rollout, public‑awareness campaigns, and integration of cancer screening into primary‑care settings. Moreover, the study's methodology—age‑standardised rates adjusted for regional heterogeneity—sets a new standard for quantifying infection‑related cancers in diverse populations. International agencies such as the WHO and IARC are already citing the Lancet paper as a reference for updating the Global Cancer Observatory's infection‑attributable cancer estimates. As India moves toward its 2030 health‑security goals, the intersection of infectious disease control and cancer prevention will likely become a cornerstone of its public‑health agenda.